Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsHyun Jung Kim, MD
Clinical InstructorAbout
Research
Publications
2026
419P 7-y survival in patients (pts) with extended-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo) in the IMpower133 (IMp133) and IMbrella A extension study, including brain (BM) and liver metastases (LM) by SCLC molecular subtype
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Breyer M, De Castro G, Bernabe R, Kim S, Kowalski D, Andric Z, Li H, Deng Y, Nabet B, Srivastava M, Oancea M, Liu S. 419P 7-y survival in patients (pts) with extended-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo) in the IMpower133 (IMp133) and IMbrella A extension study, including brain (BM) and liver metastases (LM) by SCLC molecular subtype. ESMO Open 2026, 11: 106733. DOI: 10.1016/j.esmoop.2026.106733.Peer-Reviewed Original ResearchTherapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study
Choi S, Oh S, Kim H, Park J, Choi J, Oh E, Choi J, Jeong S, Lee S, Kim J, Kim S, Kim H, Choi K, Kim J. Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study. PLOS ONE 2026, 21: e0344948. PMID: 41855149, PMCID: PMC13001945, DOI: 10.1371/journal.pone.0344948.Peer-Reviewed Original ResearchConceptsMigraine Disability Assessment ScaleHeadache Impact Test-6Open-label studyVestibular migraineInter-group differencesHeadache daysTherapeutic efficacyReferral-based university hospitalL-type calcium channel blockerHeadache Impact Test-6 scoresMulticenter open-label studyTherapeutic effectTherapeutic effect of nimodipinePain rating scaleEffect of nimodipineCalcium channel blockersEfficacy of nimodipineDizziness Handicap InventoryDisability Assessment ScaleStudy discontinuationTopiramate groupAssociated with improvementsChannel blockersFavorable tolerabilityTherapeutic optionsIntellectual disability and structural defects of the CaV2.1 channel in episodic ataxia type 2: correlation using an AI prediction model
Kim H, Lee J, Lee S, Kim S, Kim J. Intellectual disability and structural defects of the CaV2.1 channel in episodic ataxia type 2: correlation using an AI prediction model. Journal Of Neurology 2026, 273: 181. PMID: 41781521, PMCID: PMC12960376, DOI: 10.1007/s00415-026-13731-2.Peer-Reviewed Original ResearchConceptsIntellectual functioningIntellectual indicesCognitive impairmentVerbal Comprehension IndexWorking Memory IndexFull-scale IQPerceptual Reasoning IndexTM-scoreMemory indexIntellectual disabilityReasoning IndexMolecular basisWild-typeGenotype to phenotypeProtein lengthVariant proteinsProtein modelsPathogenic variantsImpairmentP/Q-type calcium channelsEpisodic ataxia type 2CaV2.1 channelsComprehensive indexProteinDiverse clinical presentationsEndoscopic resection versus surgery for T1 rectal cancer: A systematic review and meta-analysis of oncologic and safety outcomes
Moon Y, Hong Y, Kim H, Park S, Ryu H, Kwak J, Lee S, Kim J. Endoscopic resection versus surgery for T1 rectal cancer: A systematic review and meta-analysis of oncologic and safety outcomes. Surgical Endoscopy 2026, 1-10. PMID: 41772228, DOI: 10.1007/s00464-026-12674-z.Peer-Reviewed Original ResearchT1 rectal cancerDisease-free survivalEndoscopic resectionRectal cancerOverall survivalCertainty of evidencePostoperative complicationsAdverse eventsLong-term oncologic outcomesHigh riskRisk of delayed bleedingIncidence of postoperative complicationsImpaired qualityNon-randomized observational studySafety of ERMinimally invasive alternativeMeta-analysisHigher risk of deathMinor adverse eventsImpaired quality of lifeSystematic reviewROBINS-I toolRisk of deathOncological outcomesRisk of biasDeferred cytoreductive nephrectomy in patients with advanced RCC treated with first-line nivolumab plus ipilimumab: A propensity score-matched analysis from the RENOIR study (KCSG GU22-13).
Kim J, Shin S, Bae W, Kim H, Kim J, Im H, Kim I, Kim I, Park K, Kim E, Choi M, Lim J, Kim H, Lee K, Jo J, Lee H, Kim D, Lee J, Park I, Park J. Deferred cytoreductive nephrectomy in patients with advanced RCC treated with first-line nivolumab plus ipilimumab: A propensity score-matched analysis from the RENOIR study (KCSG GU22-13). Journal Of Clinical Oncology 2026, 44: 439-439. DOI: 10.1200/jco.2026.44.7_suppl.439.Peer-Reviewed Original ResearchAdvanced renal cell carcinomaDeferred cytoreductive nephrectomyObjective response rateTreatment failureComplete responseClinical characteristicsCytoreductive nephrectomyMetastatic sitesOverall survivalInternational Metastatic RCC Database Consortium risk groupClinical characteristics of patientsFirst-line nivolumabMedian TTFNear-complete responseMedian Follow-UpRenal cell carcinomaCharacteristics of patientsScore matching analysisNearest neighbor propensity score matchingMedian OSPropensity score matchingImmune-oncologyLiver metastasesPrimary tumorSystemic therapyAvelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.
Hoffman-Censits J, Tsiatas M, Chang P, Kim M, Zagouri F, Shin S, Kim H, Su H, Arija J, Maroto-Rey J, Antonuzzo L, Maruzzo M, Tambaro R, Blais N, Rottey S, Gakis G, Schneider A, Tyroller K, Jacob N, Valderrama B. Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial. Journal Of Clinical Oncology 2026, 44: 739-739. DOI: 10.1200/jco.2026.44.7_suppl.739.Peer-Reviewed Original ResearchProgression-free survivalTreatment-related adverse eventsAdvanced urothelial carcinomaPlatinum-based chemotherapyNKTR-255Overall survivalStudy's primary endpointPrimary endpointPrimary analysisFollow-upPresence of visceral metastasesFirst-line maintenanceMedian Follow-UpPhase 2 trialPhase 3 trialAnti-TIGITMetastatic UCVisceral metastasesData cutoffSacituzumab govitecanOS trendUrothelial carcinomaStudy treatmentBaseline characteristicsAdverse eventsTransforming unstructured breast cancer pathology reports into the Observational Medical Outcomes Partnership Common Data Model
Kim B, Song W, Yoon E, Kim S, Lee H, Kim J, Suh K, Kim K, Park S, Kim E, Kim S, Yoon S, Yoo S. Transforming unstructured breast cancer pathology reports into the Observational Medical Outcomes Partnership Common Data Model. BMC Medical Informatics And Decision Making 2026 PMID: 41764468, DOI: 10.1186/s12911-026-03375-7.Peer-Reviewed Original ResearchObservational Medical Outcomes PartnershipCommon data modelOMOP CDMObservational Medical Outcomes Partnership Common Data ModelTertiary general hospitalNatural language processingCancer pathology reportsAll-Cause MortalityBreast cancer pathology reportsBreast cancer pathologyPathology reportsGeneral HospitalClinical research dataBreast cancerPathological dataData modelOncology researchReceiver operating characteristic curveOperating characteristics curveBreastFeasibility studyOpen-source toolInitial pathologic diagnosisLanguage processingCancer researchThe Korean Rectal Cancer Multidisciplinary Committee Clinical Practice Guidelines for Rectal Cancer version 2.0
Ryu H, Kim H, Kang D, Kwak Y, Kwak H, Kwon Y, Kim D, Kim B, Kim J, Kim J, Kim J, Kim T, Kim H, Nam S, Noh G, Bong J, Sung N, Shin S, Lee K, Lee S, Lee S, Lee J, Lee J, Ihn M, Lim J, Ji W, Pyo D, Hong Y, Kwak J, Committee O. The Korean Rectal Cancer Multidisciplinary Committee Clinical Practice Guidelines for Rectal Cancer version 2.0. Annals Of Coloproctology 2026, 42: 4-33. PMID: 41802304, PMCID: PMC12971177, DOI: 10.3393/ac.2025.01396.0199.Peer-Reviewed Original ResearchClinical practice guidelinesCancer VersionPractice guidelinesEvidence-based clinical practice guidelinesNational health insurance systemRectal cancer outcomesLevel of evidenceHealth insurance systemEvidence synthesisPatient valuesHealthcare contextCancer outcomesSystemic treatmentRectal cancerRecommendation developmentConsensus guidelinesMultidisciplinary collaborationGuideline versionSurgical techniqueColorectal cancerClinical practiceClinical concernDiagnostic imagingInsurance systemGuidelinesAssociations Among Probable REM-sleep Behavior Disorder, Dopamine Transporter Binding, and Cognitive Performance in Parkinson Disease
Kim H, Qi Y, Goldberg T, Lee S. Associations Among Probable REM-sleep Behavior Disorder, Dopamine Transporter Binding, and Cognitive Performance in Parkinson Disease. Alzheimer Disease & Associated Disorders 2026, 40: 1-7. PMID: 41665290, DOI: 10.1097/wad.0000000000000717.Peer-Reviewed Original ResearchConceptsREM sleep behavior disorderDopamine transporter bindingTransporter bindingCognitive performanceBehavioral disordersStriatal dopamine transporter bindingSymbol Digit Modalities TestDopamine transporter activityREM Sleep Behavior Disorder Screening QuestionnairePositive screenParkinson's diseaseCognitive controlNeurobiological mechanismsStriatal dopamineDopamine transporterNeuropsychological testsCognitive changesDopamineREM sleepModal testingPRBDNo significant interactionScreening QuestionnaireSDMTProdromal marker of Parkinson's diseaseImpact of estrogen receptor expression levels on chemo-responsiveness and prognosis of breast cancer patients treated with neoadjuvant chemotherapy
Bai K, Sung H, Chung Y, Shin H, Kim E, Suh K, Kim S, Kim J, Kwon H, Park S. Impact of estrogen receptor expression levels on chemo-responsiveness and prognosis of breast cancer patients treated with neoadjuvant chemotherapy. Npj Breast Cancer 2026, 12: 37. PMID: 41634050, PMCID: PMC12976317, DOI: 10.1038/s41523-026-00907-2.Peer-Reviewed Original ResearchPositive breast cancerER-negative tumorsPatients treated with neoadjuvant chemotherapyER-lowER expression levelsNeoadjuvant chemotherapyER-negativePositive tumorsBreast cancerClinicopathological characteristicsChemo-responseClinical outcomesEstrogen receptorBreast cancer patients treated with neoadjuvant chemotherapyER-negative breast cancerResponse to NACEstrogen receptor expression levelPre-NAC biopsyProgesterone receptor-positiveResponse to chemotherapyExpression levelsReceptor expression levelsPre-NACResidual diseaseReceptor-positive